Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.

[1]  John W. Erickson,et al.  Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase , 1995, Nature Structural Biology.

[2]  N. Pattabiraman,et al.  STRUCTURAL BASIS OF DRUG RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEASE: BACKBONE FLEXIBILITY AND SUBSITE REPACKING , 1995 .

[3]  高橋 健治,et al.  Aspartic proteinases : structure, function, biology, and biomedical implications , 1995 .

[4]  J. Erickson,et al.  A quantum mechanical model of the hydration and acidity of the active site in aspartic proteases. , 1995, Advances in experimental medicine and biology.

[5]  Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine. , 1995, Advances in experimental medicine and biology.

[6]  T. Bhat,et al.  Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor , 1994, Nature Structural Biology.

[7]  James B. Dunbar,et al.  Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protease Inhibitors , 1994 .

[8]  L. Everitt,et al.  Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Dale J. Kempf,et al.  Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease , 1994 .

[10]  A. Joachimiak,et al.  Determinants of repressor/operator recognition from the structure of the trp operator binding site , 1994, Nature.

[11]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[12]  T. Bhat,et al.  Bound water molecules and conformational stabilization help mediate an antigen-antibody association. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[14]  M. Kuroda,et al.  Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor , 1994, Journal of virology.

[15]  Mark A. Murcko,et al.  Conformational analysis of HIV protease inhibitors. I. Rotation of the amide group adjacent to the P′1 decahydroisoquinoline ring system in ro 31‐8959 and related systems , 1993, J. Comput. Chem..

[16]  K. Appelt,et al.  Crystal structures of HIV-1 protease-inhibitor complexes , 1993 .

[17]  J. Erickson.  Design and structure of symmetry-based inhibitors of HIV-1 protease , 1993 .

[18]  S. Gulnik,et al.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine , 1993, Antimicrobial Agents and Chemotherapy.

[19]  R A Mueller,et al.  Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. , 1993, Journal of medicinal chemistry.

[20]  Paula M. D. Fitzgerald,et al.  HIV protease-ligand complexesCurrent Opinion in Structural Biology 1993, 3: 868874 , 1993 .

[21]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[22]  Narmada Thanki,et al.  Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling , 1992, Protein science : a publication of the Protein Society.

[23]  H Enomoto,et al.  Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. , 1992, Chemical & pharmaceutical bulletin.

[24]  C. Debouck,et al.  The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.

[25]  Axel T. Brunger,et al.  X-PLOR Version 3.1: A System for X-ray Crystallography and NMR , 1992 .

[26]  Y. Kiso,et al.  KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. , 1991, Chemical & pharmaceutical bulletin.

[27]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[28]  O. Takahashi,et al.  Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. , 1991, Chemical & pharmaceutical bulletin.

[29]  J. Huff,et al.  HIV protease: a novel chemotherapeutic target for AIDS. , 1991, Journal of medicinal chemistry.

[30]  G. Marshall,et al.  Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. , 1991, Journal of medicinal chemistry.

[31]  A. Wlodawer,et al.  The complexities of AIDS : an assessment of the HIV protease as a therapeutic target , 1991 .

[32]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. H. Yin,et al.  High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. , 1990, Gene.

[34]  Talapady N. Bhat,et al.  OMITMAP: An electron density map suitable for the examination of errors in a macromolecular model , 1984 .

[35]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.